In the most recent trading session, Eli Lilly (LLY) closed at $786.92, indicating a +1.19% shift from the previous trading day.

Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...

Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...

UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their prescribed obesity medication, according to findings published in Obesity.

Selection Follows Robust Succession Process Led by the Board - - Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors - DUBLIN, July 10, 2025 /PRNewswire/ ...

Google DeepMind subsidiary, Isomorphic Labs, has said it is ready to conduct human trials for drugs developed using its AlphaFold AI technology.

Shares of Eli Lilly & Co. LLY rose 1.19% to $786.92 Wednesday, on what proved to be an all-around great trading session for ...